Kiora Pharmaceuticals Obtains IND Approval for Phase 2 Study of KIO-101

(24/7 MARKET NEWS) – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) reported, this morning, receiving investigational new drug application approval for a Phase 2 study of KIO-101 for the treatment of the Ocular Presentation of Rheumatoid Arthritis and other autoimmune diseases (OPRA+).

Kiora is at $5.04, up $1.76 (53.66%), on 5.6 million premarket shares traded.

Its 52-week trading range is $2.32 to $39.18. Its price has fallen below the 50-day moving average in its past three trading sessions. It’s above that resistance level now and hit a premarket high of $5.70, but looks like it may have choppy trading ahead.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist